Inhibikase Therapeutics, Inc. — Balance Sheet Charts
8 snapshots of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Assets vs Liabilities
Cash Position Breakdown
Working Capital Components
Total Assets↑+83.8% +$83M
$181M
Current Assets↑+82.9% +$82M
$180M
Cash & Equivalents↑+83.4% +$81M
$179M
ST Investments↓-3.7% -$2M
$40M
Net PPE↓-100.0% -$47K
$0
Total Liabilities↑+122.3% +$5M
$8M
Current Liabilities↑+122.3% +$5M
$8M
Account Payables↑+22.8% +$215K
$1M
Long-Term Debt
—
Stockholders Equity↑+82.3% +$78M
$173M
Retained Earnings↓-51.1% -$48M
$-143M
Operating Lease ROU Asset↓-100.0% -$101K
$0
Operating Lease Liability↓-78.7% -$140K
$38K
Gross PP&E↓-100.0% -$104K
$0
Debt Due Y1
—
Debt Due Y2
—
Debt Due Y3
—
Debt Due Y4
—
Debt Due Y5
—
Total Debt Carrying Amount
—
Contract Liability
—
Contract Liability (Current)
—